Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enalapril + clonidine is a combination of two antihypertensive drugs: enalapril, an angiotensin-converting enzyme (ACE) inhibitor, and clonidine, a centrally acting alpha-2 adrenergic agonist. **Enalapril** acts primarily by inhibiting the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and lowering blood pressure. **Clonidine** works by stimulating central alpha-2 adrenoceptors, leading to decreased sympathetic outflow, which reduces peripheral vascular resistance and lowers blood pressure. Together, this combination may be used in the management of hypertension when monotherapy is insufficient, although this is not a commonly marketed fixed-dose combination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on enalapril + clonidine.